Dasari A. Shen C. Halperin D. et al.

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

JAMA Oncol. 3: 1335-1342Halfdanarson T.R. Strosberg J.R. Tang L. et al.

The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors.

Pancreas. 49: 863-881Lloyd R.V. Osamura R.Y. Kloppel G. WHO classification of tumours of endocrine organs. 4th edition. IARC, LyonChandrasekharappa S.C. Guru S. Manickam P. et al.

Positional cloning of the gene for multiple endocrine neoplasia-type 1.

Science. 276: 404-407Romanet P. Mohamed A. Giraud S. et al.

UMD-MEN1 database: an overview of the 370 MEN1 variants present in 1676 patients from the french population.

J Clin Endocrinol Metab. 104: 753-764de Laat J.M. van der Luijt R.B. Pieterman C.R. et al.

MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients.

BMC Med. 14: 182Goudet P. Murat A. Binquet C. et al.

Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.

World J Surg. 34: 249-255Thakker R.V. Newey P.J. Walls G.V. et al.

Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).

J Clin Endocrinol Metab. 97: 2990-3011Howe J.R. Merchant N.B. Conrad C. et al.

The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors.

Pancreas. 49: 1-33Falconi M. Eriksson B. Kaltsas G. et al.

ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.

Neuroendocrinology. 103: 153-171

Guidelines. NCCN Guidelines Version 1.2022 Neuroendocrine Tumors of the Pancreas (Well-Differentiated Grade 1/2). National Comprehensive Cancer Network (NCCN).

()Niederle B. Selberherr A. Bartsch D.K. et al.

Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and nonfunctioning pancreatic and duodenal neuroendocrine neoplasia within the men1 syndrome - an international consensus statement.

Neuroendocrinology. 111: 609-630Refardt J. Hofland J. Wild D. et al.

Molecular Imaging of Neuroendocrine Neoplasms.

J Clin Endocrinol Metab. 107: e2662-e2670Ambrosini V. Kunikowska J. Baudin E. et al.

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

Eur J Cancer. 146: 56-73van Beek D.J. Takkenkamp T.J. Wong-Lun-Hing E.M. et al.

Risk factors for complications after surgery for pancreatic neuroendocrine tumors.

Surgery. 172: 127-136Sallinen V. Le Large T.Y. Galeev S. et al.

Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis.

HPB (Oxford). 19: 310-320Partelli S. Cirocchi R. Crippa S. et al.

Systematic review of active surveillance versus surgical management of asymptomatic small nonfunctioning pancreatic neuroendocrine neoplasms.

Br J Surg. 104: 34-41Ricci C. Partelli S. Landoni L. et al.

Survival after active surveillance versus upfront surgery for incidental small pancreatic neuroendocrine tumours.

Br J Surg. 109: 733-738Heidsma C.M. Engelsman A.F. van Dieren S. et al.

Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA).

Br J Surg. 108: 888-891Mintziras I. Keck T. Werner J. et al.

Implementation of Current ENETS Guidelines for Surgery of Small (</=2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry.

World J Surg. 43: 175-182Lopez-Aguiar A.G. Ethun C.G. Zaidi M.Y. et al.

The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.

Surgery. 166: 15-21Partelli S. Mazza M. Andreasi V. et al.

Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life.

Surgery. 166: 157-163Sallinen V.J. Le Large TYS Tieftrunk E. et al.

Prognosis of sporadic resected small (</=2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.

HPB (Oxford). 20: 251-259Paiella S. Impellizzeri H. Zanolin E. et al.

Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors.

World J Gastroenterol. 23: 3092-3098Bettini R. Partelli S. Boninsegna L. et al.

Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor.

Surgery. 150: 75-82Rindi G. Klersy C. Albarello L. et al.

Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study.

Neuroendocrinology. 107: 375-386Tacelli M. Bina N. Crino S.F. et al.

Reliability of preoperative pancreatic neuroendocrine tumors grading on endoscopic ultrasound specimens: a systematic review with meta-analysis of aggregate and individual data.

Gastrointest Endosc. S0016-5107: 01831-01834Tanaka M. Heckler M. Mihaljevic A.L. et al.

Systematic review and metaanalysis of lymph node metastases of resected pancreatic neuroendocrine tumors.

Ann Surg Oncol. 28: 1614-1624Hong X. Qiao S. Li F. et al.

Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.

Gut. 69: 877-887Parilla M. Chapel D. Hechtman J.F. et al.

Recurrent loss of heterozygosity in pancreatic neuroendocrine tumors.

Am J Surg Pathol. 46: 823-831Jiao Y. Shi C. Edil B.H. et al.

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Science. 331: 1199-1203Scarpa A. Chang D.K. Nones K. et al.

Whole-genome landscape of pancreatic neuroendocrine tumours.

Nature. 543: 65-71Clynes D. Jelinska C. Xella B. et al.

Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.

Nat Commun. 6: 7538Wang F. Xu X. Ye Z. et al.

Prognostic significance of altered ATRX/DAXX gene in pancreatic neuroendocrine tumors: a meta-analysis.

Front Endocrinol (Lausanne). 12: 691557Hackeng W.M. Brosens L.A.A. Kim J.Y. et al.

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.

Gut. 71: 961-973Marinoni I. Kurrer A.S. Vassella E. et al.

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

Gastroenterology. 146 (): 453-460Singhi A.D. Liu T.C. Roncaioli J.L. et al.

Alternative lengthening of telomeres and loss of DAXX/ATRX Expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors.

Clin Cancer Res. 23: 600-609Hackeng W.M. Morsink F.H.M. Moons L.M.G. et al.

Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration.

Diagn Cytopathol. 48: 308-315Rindi G. Mete O. Uccella S. et al.

Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Endocr Pathol. 33: 115-154Cejas P. Drier Y. Dreijerink K.M.A. et al.

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.

Nat Med. 25: 1260-1265Dreijerink K.M. Hackeng W.M. Singhi A.D. et al.

Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.

J Pathol. 256: 143-148Oberg K. Modlin I.M. De Herder W. et al.

Consensus on biomarkers for neuroendocrine tumour disease.

Lancet Oncol. 16: e435-e446Öberg K. Califano A. Strosberg J.R. et al.

A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.

Ann Oncol. 31: 202-212van Treijen M.J.C. van der Zee D. Heeres B.C. et al.

Blood molecular genomic analysis predicts the disease course of gastroenteropancreatic neuroendocrine tumor patients: a validation study of the predictive value of the NETest.

Neuroendocrinology. 111: 586-598Paiella S. Landoni L. Tebaldi S. et al.

Dual-tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT scan and G1-G2 nonfunctioning pancreatic neuroendocrine tumors: a single-center retrospective evaluation of 124 nonmetastatic resected cases.

Neuroendocrinology. 112: 143-152Lotfalizadeh E. Ronot M. Wagner M. et al.

Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging.

Eur Radiol. 27: 1748-1759Liang W. Yang P. Huang R. et al.

A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors.

Clin Cancer Res. 25: 584-594Luo Y. Chen X. Chen J. et al.

Preoperative prediction of pancreatic neuroendocrine neoplasms grading based on enhanced computed tomography imaging: validation of deep learning with a convolutional neural network.

Neuroendocrinology. 110: 338-350Bezzi C. Mapelli P. Presotto L. et al.

Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance.

Eur J Nucl Med Mol Imaging. 48: 4002-4015van Treijen M.J.C. van Beek D.J. van Leeuwaarde R.S. et al.

Diagnosing nonfunctional pancreatic NETs in MEN1: The Evidence Base.

J Endocr Soc. 2: 1067-1088van Beek D.J. Verkooijen H.M. Nell S. et al.

Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort.

Neuroendocrinology. 111: 705-717Manoharan J. Raue F. Lopez C.L. et al.

Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?.

World J Surg. 41: 2026-2032Herath M. Parameswaran V. Thompson M. et al.

Paediatric and young adult manifestations and outcomes of multiple endocrine neoplasia type 1.

Clin Endocrinol (Oxf). 91: 633-638Goudet P. Dalac A. Le Bras M. et al.

MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'etude des Tumeurs Endocrines.

J Clin Endocrinol Metab. 100: 1568-1577Klein Haneveld M.J. van Treijen M.J.C. Pieterman C.R.C. et al.

Initiating pancreatic neuroendocrine tumour (pNET) screening in young MEN1 patients: results from the DutchMEN Study Group.

J Clin Endocrinol Metab. 106: 3515-3525Mennetrey C. Le Bras M. Bando-Delaunay A. et al.

Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease.

J Clin Endocrinol Metab. 107: e2056-e2064Cuthbertson D.J. Barriuso J. Lamarca A. et al.

The Impact of (68)Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours.

Front Endocrinol (Lausanne). 12: 654975Nell S. Borel Rinkes I.H.M. Verkooijen H.M. et al.

Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.

Ann Surg. 267: 352-356Triponez F. Sadowski S.M. Pattou F. et al.

Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small </=2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines.

Ann Surg. 268: 158-164Pieterman C.R.C. de Laat J.M. Twisk J.W.R. et al.

Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.

J Clin Endocrinol Metab. 102: 3795-3805Nell S. Verkooijen H.M. Pieterman C.R.C. et al.

Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group.

Ann Surg. 267: 1155-1160Partelli S. Tamburrino D. Lopez C. et al.

Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms </=2 cm in MEN1 Patients.

Neuroendocrinology. 103: 779-786Sadowski S.M. Pieterman C.R.C. Perrier N.D. et al.

Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Endocrine-related cancer. 27: R145-R161de Wilde R.F. Heaphy C.M. Maitra A. et al.

Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.

Mod Pathol. 25: 1033-1039Fahrmann J.F. Wasylishen A.R. Pieterman C.R.C. et al.

A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.

J Clin Endocrinol Metab. 106: e4969-e4980Lastoria S. Marciello F. Faggiano A. et al.

Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).

Endocrine. 52: 488-494Kornaczewski Jackson E.R. Pointon O.P. Bohmer R. et al.

Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.

J Clin Endocrinol Metab. 102: 1926-1933Garg R. Mohammed A. Singh A. et al.

EUS-guided radiofrequency and ethanol ablation for pancreatic neuroendocrine tumors: A systematic review and meta-analysis.

Endosc Ultrasound. 11: 170-185Rimbaş M. Horumbă M. Rizzatti G. et al.

Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms.

Dig Endosc. 32: 1031-1041Hehakaya C. Sharma A.M. van der Voort Van Zijp J.R.N. et al.

Implementation of Magnetic Resonance Imaging-Guided Radiation Therapy in Routine Care: Opportunities and Challenges in the United States.

Adv Radiat Oncol. 7: 100953Caplin M.E. Pavel M. Cwikla J.B. et al.

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

N Engl J Med. 371: 224-233Caplin M.E. Pavel M. Cwikla J.B. et al.

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

Endocrine-related cancer. 23: 191-199Lopez C.L. Joos B. Bartsch D.K. et al.

Chemoprevention with Somatuline(c) Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).

World J Surg. 43: 831-838Quinn T.J. Yuan Z. Adem A. et al.

Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.

Surgery. 152: 1068-1077Walls G.V. Stevenson M. Soukup B.S. et al.

Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.

Endocrinology. 157: 1789-1798Ramundo V. Del Prete M. Marotta V. et al.

Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.

Clin Endocrinol. 80: 850-855Cioppi F. Cianferotti L. Masi L. et al.

The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.

Clin cases mineral bone Metab. 14: 123-130Faggiano A. Modica R. Lo Calzo F. et al.

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.

J Clin Endocrinol Metab. 105Pieterman C.R.C. Valk G.D.

Update on the clinical management of multiple endocrine neoplasia type 1.

Clin Endocrinol (Oxf). 97: 409-423Pieterman C.R.C. van Leeuwaarde R.S. van den Broek M.F.M. et al.

Multiple Endocrine Neoplasia Type 1.

in: Feingold K.R. Anawalt B. Boyce A. Endotext. MDText.com, Inc.Copyright, South Dartmouth (MA) ()Kim H.S. Lee H.S. Nam K.H. et al.

p27 Loss is associated with poor prognosis in gastroenteropancreatic neuroendocrine tumors.

Cancer Res Treat. 46: 383-392Uemura J. Okano K. Oshima M. et al.

Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.

Ann Surg. 274: e949-e956Missiaglia E. Dalai I. Barbi S. et al.

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.

J Clin Oncol. 28: 245-255Puccini A. Poorman K. Salem M.E. et al.

Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).

Clin Cancer Res. 26: 5943-5951Roy S. LaFramboise W.A. Liu T.C. et al.

Loss of chromatin-remodeling proteins and/or CDKN2A associates with metastasis of pancreatic neuroendocrine tumors and reduced patient survival times.

Gastroenterology. 154: 2060-2063 e2068Han X. Chen W. Chen P. et al.

Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors.

Pancreas. 49: 514-523Yachida S. Vakiani E. White C.M. et al.

Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Am J Surg Pathol. 36: 173-184